(Q30959521)

English

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 August 2017

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples (English)

1 reference

Europe PubMed Central

10 August 2017

1 reference

based on heuristic

inferred from title

author name string

M Tanner

1

1 reference

Europe PubMed Central

10 August 2017

D Gancberg

2

1 reference

Europe PubMed Central

10 August 2017

A Di Leo

3

1 reference

Europe PubMed Central

10 August 2017

D Larsimont

4

1 reference

Europe PubMed Central

10 August 2017

G Rouas

5

1 reference

Europe PubMed Central

10 August 2017

M J Piccart

6

1 reference

Europe PubMed Central

10 August 2017

J Isola

7

1 reference

Europe PubMed Central

10 August 2017

language of work or name

0 references

publication date

1 November 2000

1 reference

Europe PubMed Central

10 August 2017

The American Journal of Pathology

1 reference

Europe PubMed Central

10 August 2017

157

1 reference

Europe PubMed Central

10 August 2017

1467-1472

1 reference

Europe PubMed Central

10 August 2017

5

1 reference

Europe PubMed Central

10 August 2017

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885742

21 June 2018

The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885742

21 June 2018

Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885742

21 June 2018

HER-2/neu (c-erb-B2) gene and protein in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885742

21 June 2018

Subtracted, unique-sequence, in situ hybridization: experimental and diagnostic applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885742

21 June 2018

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885742

21 June 2018

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885742

21 June 2018

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885742

21 June 2018

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885742

21 June 2018

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2964785-2

7 January 2021

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2964785-2

7 January 2021

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2964785-2

7 January 2021

The HercepTest assay: another perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2964785-2

7 January 2021

Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2964785-2

7 January 2021

Multi-colour brightfield in situ hybridisation on tissue sections

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2964785-2

7 January 2021

Efficient nuclear FISH on paraffin-embedded tissue sections using microwave pretreatment

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2964785-2

7 January 2021

Identifiers

10.1016/S0002-9440(10)64785-2

1 reference

Europe PubMed Central

10 August 2017

release_7oyerb3w7zhwbdgf4oxulf5pvu

1 reference

https://api.fatcat.wiki/v0/release/7oyerb3w7zhwbdgf4oxulf5pvu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30959521&oldid=1966909968"